Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

Francesca J. Torriani, Maribel Rodriguez-Torres, Jürgen K. Rockstroh, Eduardo Lissen, Juan Gonzalez-García, Adriano Lazzarin, Giampiero Carosi, Joseph Sasadeusz, Christine Katlama, Julio Montaner, Hoel Sette, Sharon Passe, Jean De Pamphilis, Frank Duff, Uschi Marion Schrenk, Douglas T. Dieterich

Research output: Contribution to journalArticle

1145 Citations (Scopus)

Abstract

BACKGROUND: Hepatitis C virus (HCV) infection is highly prevalent and is associated with substantial morbidity and mortality among persons infected with the human immunodeficiency virus (HIV). We compared the efficacy and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either ribavirin or placebo with those of interferon alfa-2a plus ribavirin for the treatment of chronic HCV infection in patients who were also infected with HIV. METHODS: A total of 868 persons who were infected with both HIV and HCV and who had not previously been treated with interferon or ribavirin were randomly assigned to receive one of three regimens: peginterferon alfa-2a (180 μg per week) plus ribavirin (800 mg per day), peginterferon alfa-2a plus placebo, or interferon alfa-2a (3 million IU three times a week) plus ribavirin. Patients were treated for 48 weeks and followed for an additional 24 weeks. The primary end point was a sustained virologic response (defined as a serum HCV RNA level below 50 IU per milliliter at the end of follow-up, at week 72). RESULTS: The overall rate of sustained virologic response was significantly higher among the recipients of peginterferon alfa-2a plus ribavirin than among those assigned to interferon alfa-2a plus ribavirin (40 percent vs. 12 percent, P

Original languageEnglish
Pages (from-to)438-450
Number of pages13
JournalNew England Journal of Medicine
Volume351
Issue number5
DOIs
Publication statusPublished - Jul 29 2004

Fingerprint

Ribavirin
Chronic Hepatitis C
Virus Diseases
Hepacivirus
HIV
Placebos
peginterferon alfa-2a
Interferons
RNA
Morbidity
Safety
Mortality
Serum
interferon alfa-2a

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-García, J., Lazzarin, A., ... Dieterich, D. T. (2004). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine, 351(5), 438-450. https://doi.org/10.1056/NEJMoa040842

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. / Torriani, Francesca J.; Rodriguez-Torres, Maribel; Rockstroh, Jürgen K.; Lissen, Eduardo; Gonzalez-García, Juan; Lazzarin, Adriano; Carosi, Giampiero; Sasadeusz, Joseph; Katlama, Christine; Montaner, Julio; Sette, Hoel; Passe, Sharon; De Pamphilis, Jean; Duff, Frank; Schrenk, Uschi Marion; Dieterich, Douglas T.

In: New England Journal of Medicine, Vol. 351, No. 5, 29.07.2004, p. 438-450.

Research output: Contribution to journalArticle

Torriani, FJ, Rodriguez-Torres, M, Rockstroh, JK, Lissen, E, Gonzalez-García, J, Lazzarin, A, Carosi, G, Sasadeusz, J, Katlama, C, Montaner, J, Sette, H, Passe, S, De Pamphilis, J, Duff, F, Schrenk, UM & Dieterich, DT 2004, 'Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients', New England Journal of Medicine, vol. 351, no. 5, pp. 438-450. https://doi.org/10.1056/NEJMoa040842
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine. 2004 Jul 29;351(5):438-450. https://doi.org/10.1056/NEJMoa040842
Torriani, Francesca J. ; Rodriguez-Torres, Maribel ; Rockstroh, Jürgen K. ; Lissen, Eduardo ; Gonzalez-García, Juan ; Lazzarin, Adriano ; Carosi, Giampiero ; Sasadeusz, Joseph ; Katlama, Christine ; Montaner, Julio ; Sette, Hoel ; Passe, Sharon ; De Pamphilis, Jean ; Duff, Frank ; Schrenk, Uschi Marion ; Dieterich, Douglas T. / Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. In: New England Journal of Medicine. 2004 ; Vol. 351, No. 5. pp. 438-450.
@article{0777c07b5fab4c3a85e97e0591ae873e,
title = "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients",
abstract = "BACKGROUND: Hepatitis C virus (HCV) infection is highly prevalent and is associated with substantial morbidity and mortality among persons infected with the human immunodeficiency virus (HIV). We compared the efficacy and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either ribavirin or placebo with those of interferon alfa-2a plus ribavirin for the treatment of chronic HCV infection in patients who were also infected with HIV. METHODS: A total of 868 persons who were infected with both HIV and HCV and who had not previously been treated with interferon or ribavirin were randomly assigned to receive one of three regimens: peginterferon alfa-2a (180 μg per week) plus ribavirin (800 mg per day), peginterferon alfa-2a plus placebo, or interferon alfa-2a (3 million IU three times a week) plus ribavirin. Patients were treated for 48 weeks and followed for an additional 24 weeks. The primary end point was a sustained virologic response (defined as a serum HCV RNA level below 50 IU per milliliter at the end of follow-up, at week 72). RESULTS: The overall rate of sustained virologic response was significantly higher among the recipients of peginterferon alfa-2a plus ribavirin than among those assigned to interferon alfa-2a plus ribavirin (40 percent vs. 12 percent, P",
author = "Torriani, {Francesca J.} and Maribel Rodriguez-Torres and Rockstroh, {J{\"u}rgen K.} and Eduardo Lissen and Juan Gonzalez-Garc{\'i}a and Adriano Lazzarin and Giampiero Carosi and Joseph Sasadeusz and Christine Katlama and Julio Montaner and Hoel Sette and Sharon Passe and {De Pamphilis}, Jean and Frank Duff and Schrenk, {Uschi Marion} and Dieterich, {Douglas T.}",
year = "2004",
month = "7",
day = "29",
doi = "10.1056/NEJMoa040842",
language = "English",
volume = "351",
pages = "438--450",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "5",

}

TY - JOUR

T1 - Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

AU - Torriani, Francesca J.

AU - Rodriguez-Torres, Maribel

AU - Rockstroh, Jürgen K.

AU - Lissen, Eduardo

AU - Gonzalez-García, Juan

AU - Lazzarin, Adriano

AU - Carosi, Giampiero

AU - Sasadeusz, Joseph

AU - Katlama, Christine

AU - Montaner, Julio

AU - Sette, Hoel

AU - Passe, Sharon

AU - De Pamphilis, Jean

AU - Duff, Frank

AU - Schrenk, Uschi Marion

AU - Dieterich, Douglas T.

PY - 2004/7/29

Y1 - 2004/7/29

N2 - BACKGROUND: Hepatitis C virus (HCV) infection is highly prevalent and is associated with substantial morbidity and mortality among persons infected with the human immunodeficiency virus (HIV). We compared the efficacy and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either ribavirin or placebo with those of interferon alfa-2a plus ribavirin for the treatment of chronic HCV infection in patients who were also infected with HIV. METHODS: A total of 868 persons who were infected with both HIV and HCV and who had not previously been treated with interferon or ribavirin were randomly assigned to receive one of three regimens: peginterferon alfa-2a (180 μg per week) plus ribavirin (800 mg per day), peginterferon alfa-2a plus placebo, or interferon alfa-2a (3 million IU three times a week) plus ribavirin. Patients were treated for 48 weeks and followed for an additional 24 weeks. The primary end point was a sustained virologic response (defined as a serum HCV RNA level below 50 IU per milliliter at the end of follow-up, at week 72). RESULTS: The overall rate of sustained virologic response was significantly higher among the recipients of peginterferon alfa-2a plus ribavirin than among those assigned to interferon alfa-2a plus ribavirin (40 percent vs. 12 percent, P

AB - BACKGROUND: Hepatitis C virus (HCV) infection is highly prevalent and is associated with substantial morbidity and mortality among persons infected with the human immunodeficiency virus (HIV). We compared the efficacy and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either ribavirin or placebo with those of interferon alfa-2a plus ribavirin for the treatment of chronic HCV infection in patients who were also infected with HIV. METHODS: A total of 868 persons who were infected with both HIV and HCV and who had not previously been treated with interferon or ribavirin were randomly assigned to receive one of three regimens: peginterferon alfa-2a (180 μg per week) plus ribavirin (800 mg per day), peginterferon alfa-2a plus placebo, or interferon alfa-2a (3 million IU three times a week) plus ribavirin. Patients were treated for 48 weeks and followed for an additional 24 weeks. The primary end point was a sustained virologic response (defined as a serum HCV RNA level below 50 IU per milliliter at the end of follow-up, at week 72). RESULTS: The overall rate of sustained virologic response was significantly higher among the recipients of peginterferon alfa-2a plus ribavirin than among those assigned to interferon alfa-2a plus ribavirin (40 percent vs. 12 percent, P

UR - http://www.scopus.com/inward/record.url?scp=3343012408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3343012408&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa040842

DO - 10.1056/NEJMoa040842

M3 - Article

VL - 351

SP - 438

EP - 450

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 5

ER -